NCT03069469 - Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2028

Conditions

Advanced Malignant NeoplasmPigmented Villonodular SynovitisGiant Cell Tumor of Tendon SheathTenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, Diffuse

Interventions

DRUG

Vimseltinib

Colony-stimulating factor 1 receptor (CSF1R) inhibitor

Trial Locations (24)

10065

MSKCC, New York

32224

Mayo Clinic, Jacksonville

33136

University of Miami, Miami

37203

Sarah Cannon Research Institute, Nashville

80204

University of Colorado - Denver, Denver

94304

Stanford Cancer Institute, Palo Alto

97239

OHSU, Portland

Oregon Health & Science University, Portland

02215

Dana Farber, Boston

Unknown

Peter MacCallum Cancer Centre, Melbourne

McGill University Health Centre, Montreal

Princess Margaret Cancer Center, Toronto

Centre Leon Berard, Lyon

Gustave Roussy Cancer Campus Grand Paris, Paris

IRCCS Istituto Ortopedico Rizzoli, Bologna

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan

Istituto Nazionale dei Tumori, Milan

Regina Elena National Cancer Institute, Rome

Leiden University Medical Center, Leiden

M. Sklodowska-Curie Memorial Cancer Center, Warsaw

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Clinico San Carlos, Madrid

Hospital Universitario Virgen del Rocío, Sevilla, Seville

University College Hospital, London